IP Library Granted Patent US 9,790,285
Granted Patent B2
US 9,790,285 · App. 14/550,796 · Granted Oct 17, 2017

Anti-CD38 antibodies

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,790,285
App. No.
14/550,796
Granted
Oct 17, 2017
Kind
B2
Abstract

Isolated antibodies that bind to human CD38 and cynomolgus CD38 are disclosed. Also disclosed are pharmaceutical compositions comprising the disclosed antibodies, and therapeutic and diagnostic methods for using the disclosed antibodies.

Claims (46)

1. An isolated nucleic acid encoding the heavy chain of an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) wherein the heavy chain variable region comprises SEQ ID NO:9.

2. An isolated nucleic acid encoding the light chain of an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) wherein the light chain variable region comprises SEQ ID NO:10.

3. An isolated nucleic acid composition comprising:

i) a first nucleic acid encoding a heavy chain variable region comprising:

i) a first CDR comprising SEQ ID NO:3;

ii) a second CDR comprising SEQ ID NO:4;

iii) a third CDR comprising SEQ ID NO:5; and

ii) a second nucleic acid encoding a light chain variable region comprising:

i) a first CDR comprising SEQ ID NO:6;

ii) a second CDR comprising SEQ ID NO:7;

iii) a third CDR comprising SEQ ID NO:8.

4. An isolated nucleic acid composition according to claim 3 wherein said first nucleic acid encodes SEQ ID NO:9 and said second nucleic acid encodes SEQ ID NO:10.

5. An isolated nucleic acid composition according to claim 4 wherein said first nucleic acid encodes SEQ ID NO:21 and said second nucleic acid encodes SEQ ID NO:22.

6. A host cell comprising the isolated nucleic acid of claim 3 .

7. A host cell comprising the isolated nucleic acid of claim 4 .

8. A host cell comprising the isolated nucleic acid of claim 5 .

9. A method of producing an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising culturing the host cell of claim 6 under conditions wherein said antibody is produced.

10. A method of producing an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising culturing the host cell of claim 7 under conditions wherein said antibody is produced.

11. A method of producing an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising culturing the host cell of claim 8 under conditions wherein said antibody is produced.

12. An isolated nucleic acid encoding the heavy chain of an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) wherein the heavy chain variable region comprises:

i) a first CDR comprising SEQ ID NO:13;

ii) a second CDR comprising SEQ ID NO:14;

iii) a third CDR comprising SEQ ID NO:15.

13. An isolated nucleic acid encoding the light chain of an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) wherein the light chain variable region comprises:

i) a first CDR comprising SEQ ID NO:16;

ii) a second CDR comprising SEQ ID NO:17;

iii) a third CDR comprising SEQ ID NO:18.

14. An isolated nucleic acid encoding the heavy chain of an antibody according to claim 12 wherein said heavy chain comprises SEQ ID NO:11.

15. An isolated nucleic acid encoding the light chain of an antibody according to claim 13 wherein said light chain comprises SEQ ID NO:12.

16. An isolated nucleic acid composition comprising:

i) a first nucleic acid encoding a heavy chain variable region comprising:

i) a first CDR comprising SEQ ID NO:13;

ii) a second CDR comprising SEQ ID NO:14;

iii) a third CDR comprising SEQ ID NO:15; and

ii) a second nucleic acid encoding a light chain variable region comprising:

i) a first CDR comprising SEQ ID NO:16;

ii) a second CDR comprising SEQ ID NO:17;

iii) a third CDR comprising SEQ ID NO:18.

17. An isolated nucleic acid composition according to claim 16 wherein said first nucleic acid encodes SEQ ID NO:11 and said second nucleic acid encodes SEQ ID NO:12.

18. An isolated nucleic acid composition according to claim 17 wherein said first nucleic acid encodes SEQ ID NO:19 and said second nucleic acid encodes SEQ ID NO:20.

19. A host cell comprising the isolated nucleic acid of claim 16 .

20. A host cell comprising the isolated nucleic acid of claim 17 .

21. A host cell comprising the isolated nucleic acid of claim 18 .

22. A method of producing an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising culturing the host cell of claim 19 under conditions wherein said antibody is produced.

23. A method of producing an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising culturing the host cell of claim 20 under conditions wherein said antibody is produced.

24. A method of producing an antibody which specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising culturing the host cell of claim 21 under conditions wherein said antibody is produced.

Assignments (6)
CORRECTION AND RELEASE OF SECURITY AGREEMENT Recorded Jan 14, 2025
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 069895/0584 →
SECURITY INTEREST Recorded May 9, 2018
From: XOMA (US) LLC
To: SILICON VALLEY BANK
Reel/Frame 046115/0408 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: ELIAS, KATHLEEN ANN; LANDES, GREGORY; SINGH, SHWETA; KORVER, WOUTER; DRAKE, ANDREW WALLING; HAAK-FRENDSCHO, MARY; SNELL, GYORGY PAL
To: TAKEDA CALIFORNIA, INC.
Reel/Frame 035489/0328 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: BHASKAR, VINAY
To: XOMA (US) LLC
Reel/Frame 035489/0428 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: XOMA (US) LLC
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 035489/0457 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 24, 2015
From: TAKEDA CALIFORNIA, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 035489/0526 →